Bookmark

Add to MyYahoo RSS

Amgen News

News on Amgen (Ticker: AMGN) continually updated from thousands of sources around the net.

10 hrs ago | Applied Clinical Trials

FDA Grants Amgen Priority Review Designation For Ivabradine For The...

Ivabradine is an oral drug that inhibits the I f current in the sinoatrial node, the body's cardiac pacemaker.1 Ivabradine works to slow the heart rate without negative effects on myocardial contractility or ventricular repolarization.1 Heart failure is a common condition that affects approximately 26 million worldwide, including approximately 5.1 ... (more)

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Healthcare Law, Law, Food and Drug Administration, Marketing

11 hrs ago | TheStreet.com

Why Amgen (AMGN) Stock Hit a One-Year High Today

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Mozilla, Food and Drug Administration

12 hrs ago | Seeking Alpha

Why Amgen Stock Is A Long-Term Investment Opportunity

Amgen Inc. will continue to benefit from the growing demand for its products, and from its top-quality pipeline that should sustain long-term growth.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Amgen, Enbrel, Etanercept (generic), Financial Markets

Mon Aug 25, 2014

Freshnews

Timothy Leyden Retires As Western Digital CFO, Succeeded By Olivier...

Western Digital Corp. today announced that chief financial officer Tim Leyden, 62, is retiring after 24 years of distinguished service at the company.

Comment?

Related Topix: Western Digital Corporation, Computers, Western Digital, Biotech, Medicine, Healthcare Industry, Dell

AmericanBankingNews.com

Amgen Reaches New 12-Month High at $134.93

Amgen 's share price hit a new 52-week high during mid-day trading on Monday , Stock Ratings Network.com reports.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Amgen

Sun Aug 24, 2014

Boston.com

Biopharmaceutical companies shifting labs, jobs to Mass.

A wave of biopharmaceutical industry consolidation has been bringing jobs and companies to Massachusetts even as it has led to darkened labs and uprooted scientists in other states.

Comment?

Related Topix: Massachusetts, Massachusetts Government, Marlborough, MA, Biotech, Science / Technology, Medicine, Healthcare Industry, Cambridge, MA

Fri Aug 22, 2014

Value Line

June 30, 2014 Mid Year Mutual Fund Review

The stock market continued its forward move during the second quarter of 2014. The Dow gained a modest 2.2% during the second quarter, while achieving a 7.9% return year to date.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry

Seeking Alpha

These 2 Stocks Could Be Winners Because Plenty Of People Want To Look Younger

Both Kythera Biopharmaceuticals and Revance Therapeutics are developing first in class drug candidates that have significant potential in the $10 billion cosmetic procedure market.

Comment?

Related Topix: Revance Therapeutics, Allergan, Biotech, Food and Drug Administration, Medicine, Healthcare Industry

Seeking Alpha

Tracking Dan Loeb's Third Point Portfolio - Q2 2014 Update

Loeb's 13F portfolio increased 19% this quarter from $6.8B to $8.1B. The number of positions decreased from 47 to 41. Third Point established a huge new 13.39% of the US long portfolio position in Ally Financial as a result of their IPO in April.

Comment?

Related Topix: Economics News, Bankruptcy, Activism, FMC, Chemicals, Biotech, Medicine, Healthcare Industry, Finisar, Startups

Thu Aug 21, 2014

Reuters

UPDATE 2-Lilly psoriasis drug impresses; battle nears with Amgen, Novartis

An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Psoriasis, Health, Enbrel, Etanercept (generic), Eli Lilly, Marketing

Seeking Alpha

Amgen Has Yet To Reach Its Potential, Despite Strong Gains

With shares of Amgen trading at near 52-week highs, investors are getting nervous about the next couple of quarters.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Johnson and Johnson, Pfizer, GlaxoSmithKline

Tue Aug 19, 2014

Business Journal

Amgen enters heavyweight fray for Kendall Square's few remaining blocks of space

As if things couldn't get more competitive in East Cambridge's office and lab market: Drug giant Amgen Inc. is on the prowl for another 150,000 square feet of space.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bristol Myers Squibb

Business Journal

Amgen enters heavyweight fray for Kendall Square's few remaining blocks of space

Amgen is on the hunt for 150,000 square feet of space in Cambridge, although a spokewoman said the long-term plan is to build out the company's existing footprint at 360 Binney St. .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Boston, MA, Bloomsbury Publishing, Bristol Myers Squibb, Publishing, Media, Medarex

BayStreet.ca

A New Cannabinoid-based Arthritis Therapy in the Making

WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states.

Comment?

Related Topix: Medicine, Arthritis, Health, Marijuana, Whitefish, MT, US Energy Systems, Energy, Biotech, Healthcare Industry, Allergan

Mon Aug 18, 2014

Reuters

Amgen thyroid drug succeeds in late-stage trial

Drugmaker Amgen Inc said its experimental drug to reduce thyroid levels in patients with chronic kidney disease met the main goal in a late-stage trial.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Sys-Con Media

Amgen Announces Positive Top-Line Results From Second Phase 3 Study...

The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone levels during an Efficacy Assessment Phase defined as the period between weeks 20 and 27. These results follow the recent announcement of positive data from a prior placebo-controlled Phase 3 study of AMG 416 which was similar in ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Amgen

BioSpace

Good News For Amgen As Thyroid Drug AMG 416 Succeeds In Phase 3 Study

Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis Second Phase 3 Registrational Study Meets Primary and All Secondary Endpoints AMG 416 is a Novel Calcimimetic Administered Intravenously /PRNewswire/ -- ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Amgen

Sat Aug 16, 2014

Seeking Alpha

General Electric: The Good, The Bad, The Ugly

GE is a huge conglomerate with lots of moving parts and that is a risk in of itself which investors should be aware of before investing in the company.

Comment?

Related Topix: General Electric, Financial Services, Aerospace-Defense, Alternative Energy, Renewable Energy (Green Energy), Energy, Wind Power, Stanley, Biotech, Medicine, Healthcare Industry

Fri Aug 15, 2014

Forbes.com

Thursday Sector Leaders: Utilities, Healthcare

The best performing sector as of midday Thursday is the Utilities sector, higher by 0.9%.

Comment?

Related Topix: Pinnacle West Capital Corporation, Energy, Duke Energy, Financial Markets, Biotech, Medicine, Amgen, Healthcare Industry, Perrigo

Live Charts

US close: Stocks edge higher after remarks from Putin

Russian President Vladimir Putin said Russia will do everything it can to stop the conflict in eastern Ukraine.

Comment?

Related Topix: Financial Markets, Vladimir Putin, Retail, Kohls, Biotech, Medicine, Healthcare Industry, Startups, Cisco Systems

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••